Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | TNF | P01375 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11739254 | 0.98 | CYP1A2 (0.52) | CYP1A2CYP2A6TNFGAAKDM4E | |
| SCHEMBL3805113 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2A6GAAKDM4ELMNA | |
| SCHEMBL30070982 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2A6GAAKDM4ELMNA | |
| SCHEMBL30477305 | 0.76 | TNF (0.55) | CYP1A2TNFKDM4ELMNACYP3A4 | |
| SCHEMBL197053 | 0.74 | TNF (0.53) | CYP1A2TNFKDM4ELMNACYP3A4 | |
| SCHEMBL276527 | 0.74 | TNF (0.53) | CYP1A2TNFKDM4ELMNACYP3A4 | |
| SCHEMBL1771760 | 0.74 | TNF (0.53) | CYP1A2TNFKDM4ELMNACYP3A4 | |
| SCHEMBL276528 | 0.74 | KDM4E (0.70) | CYP1A2TNFKDM4ELMNACYP3A4 | |
| SCHEMBL256939 | 0.74 | CYP2A6 (0.54) | CYP1A2CYP2A6TNFKDM4ELMNA | |
| SCHEMBL1351336 | 0.74 | TNF (0.53) | CYP1A2TNFKDM4ELMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117801596-B | Photosensitive polyimide resin composition and preparation method and application thereof | 深圳先进电子材料国际创新研究院 | 2025-04-25 | — | — | CN | claimed |
| CN-112500342-A | Synthesis method of 8-methoxyisoquinoline | 苏州康润医药有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-106966977-A | The synthetic method of 8 isoquinolinols | 徐州医科大学 | 2017-07-21 | — | — | CN | claimed |
| US-4795621-A | CATALYST OF QUINOLINE COMPOUND AND METAL COMPOUND | SHIN NISSO KAKO CO., LTD. (JP) | 1989-01-03 | — | — | US | claimed |
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4558479-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-117801596-B | Photosensitive polyimide resin composition and preparation method and application thereof | 深圳先进电子材料国际创新研究院 | 2025-04-25 | — | — | CN | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20070060739-A1 | Process for producing phosphonitrilic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| CN-1886378-A | 1,4-disubstituted isoquinilone derivatives as RAF-kinase inhibitors useful for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2006-12-27 | — | — | CN | disclosed |
| US-7090813-B2 | Method for producing cyclic chlorophosphazene oligomers | ASAKI KASEI CHEMICALS CORPORATION (JP) | 2006-08-15 | — | — | US | disclosed |
| EP-1667980-A1 | 1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028444-A1 | 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20040146443-A1 | Method for producing cyclic chlorophosphazene oligomers | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2004-07-29 | — | — | US | disclosed |
| US-4795621-A | CATALYST OF QUINOLINE COMPOUND AND METAL COMPOUND | SHIN NISSO KAKO CO., LTD. (JP) | 1989-01-03 | — | — | US | disclosed |
| US-4585472-A | PRE- AND POSTEMERGENCE HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1986-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP1A2 3570/4885CYP2A6 3140/4885TNF 172/4885 |
| US-20250375526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP1A2 3570/4885CYP2A6 3140/4885TNF 172/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | CYP1A2 2455/4885CYP2A6 781/4885TNF 3470/4885 |
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | CBR3, HAX1, CBR1 | CYP1A2 520/4885CYP2A6 868/4885TNF 4790/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CYP1A2 2027/4885CYP2A6 1135/4885TNF 4483/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CYP1A2 74/4885CYP2A6 604/4885TNF 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.